Closing of transaction following the receipt of all required regulatory approvals TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industries Clients include blue-chip companies from biotech and pharma sectors across Europe Exyte CEO Büchele: "The acquisition of TTP brings additional engineering expertise, experience, and business opportunities to Exyte, particularly in the thriving European biopharma and life sciences markets." STUTTGART, Germany , Nov. 5, 2024 /PRNewswire/ -- Exyte, a global leader in the design, engineering, and delivery of high-tech facilities, has successfully completed the acquisition of TTP Group ("TTP").
The transaction, announced in September 2024 , has closed following the receipt of all required regulatory approvals. TTP is a specialized and trusted partner for blue-chip clients in the biotech, pharma and chemical industries across Europe . The company, through its two operational brands 'Pharmaplan' and 'Triplan', covers the entire service spectrum from Engineering to Procurement, Construction Management, and Validation.
Exyte will combine TTP's operations with its own Biopharma and Life Sciences activities in Europe , aiming to establish an even stronger partnership with the rapidly growing European biotechnology and pharmaceutical sectors. This acquisition further solidifies Exyte's position as a global player in the pharma market, enhancing its presence and capabilities in Europe . Exyte CEO Dr.
Wolfgang Bü.
